June 28, 2007 - CryoCor Inc., a medical device company focused on the treatment of cardiac arrhythmias, announced that the FDA Advisory Panel recommended that CryoCor’s application for pre-market approval (PMA) for the treatment of atrial flutter be approved by the FDA.
The meeting of the Advisory Panel was held on June 27, 2007 and a decision from the FDA on CryoCor's PMA is expected in August 2007.
"We are pleased with the decision by the Advisory Panel to recommend our PMA for approval and look forward to the FDA’s decision in August,” said Helen Barold, M.D.
For more information: www.cryocor.com